Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting
JAMA Internal Medicine2019Vol. 179(3), pp. 324–324
Citations Over TimeTop 10% of 2019 papers
Abstract
The rates of complications after invasive diagnostic procedures were higher than the rates reported in clinical trials. Physicians and patients should be aware of the potential risks of subsequent adverse events and their high downstream costs in the shared decision-making process.
Related Papers
- → Lung Cancer Screening: Advantages, Controversies, and Applications(2014)168 cited
- → Commentary: Black Lives Matter—Why We Need to Fix Racial Disparities in Lung Cancer Screening(2020)1 cited
- → Implementation of a Lung Cancer-Screening Program(2013)1 cited
- → Determination of the optimal screen interval in low-dose CT lung cancer screening: are we there yet?(2016)1 cited
- → How to diagnose pulmonary nodules: from screening to therapy(2017)